Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N07XX07
|
| gptkbp:brand |
gptkb:Fampyra
dalfampridine |
| gptkbp:CASNumber |
22662-39-1
|
| gptkbp:chemicalClass |
pyridine derivative
|
| gptkbp:chemicalFormula |
C5H6N2
|
| gptkbp:contraindication |
history of seizures
moderate or severe renal impairment |
| gptkbp:eliminatedIn |
renal
|
| gptkbp:halfLife |
5-6 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ampyra
|
| gptkbp:improves |
walking in multiple sclerosis patients
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Acorda_Therapeutics
|
| gptkbp:mechanismOfAction |
potassium channel blocker
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
Rx-only
|
| gptkbp:routeOfAdministration |
oral tablet
|
| gptkbp:sideEffect |
urinary tract infection
seizures insomnia |
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:fampridine
|
| gptkbp:bfsLayer |
7
|